Early results from clinical trials on substances like MDMA and psilocybin have been encouraging. In the middle of what is often regarded as a mental health crisis, many of these initiatives target a few of the most expensive and challenging mental health conditions while they are still happening. Researchers and executives discussed how that might convince health insurers, or “payors,” to jump on board during a Perspective on Psychedelics conference in New York.
Members of Outlawz have said for years that they mixed some of Tupac Shakur’s ashes…
State and local police made at least 218,152 marijuana-related arrests in 2025, including 200,960 for…
Three days in Philadelphia, September 25 to 27, with a free record-clearing clinic and a…
Four decades after its Amsterdam beginnings, Barney’s Farm is marking the milestone with new markets,…
Gallup’s new numbers hold a small, awkward pattern: the Americans most convinced cannabis is bad…
The FDA is seeking outside data and analytics services to better understand how people use…